{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:36:47Z","timestamp":1793371007690,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jaad.2026.07.093","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:19:46Z","timestamp":1785453586000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoding biological drug names in dermatology: The post-2022 WHO nomenclature revision and its implications for clinical practice"],"prefix":"10.1016","author":[{"given":"Shrishti","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugal Kishor","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayush","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2026.07.093_bib3","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2022.2075078","article-title":"International nonproprietary names for monoclonal antibodies: an evolving nomenclature system","volume":"14","author":"Guimaraes Koch","year":"2022","journal-title":"MAbs"},{"key":"10.1016\/j.jaad.2026.07.093_bib4","series-title":"New INN Monoclonal Antibody (mAb) Nomenclature Scheme. INN Working Document 22.542","year":"2022"},{"issue":"24","key":"10.1016\/j.jaad.2026.07.093_bib5","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1111\/bph.15953","article-title":"No new 'mabs' in medicine-new nomenclature for monoclonal antibodies","volume":"179","author":"Lythgoe","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jaad.2026.07.093_bib6","series-title":"The use of stems in the selection of International Nonproprietary Names (INN) for Pharmaceutical Substances. WHO\/EMP\/RHT\/TSN\/2018.1","year":"2018"},{"issue":"18","key":"10.1016\/j.jaad.2026.07.093_bib7","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1056\/NEJMoa2504187","article-title":"Oral icotrokinra for plaque psoriasis in adults and adolescents","volume":"393","author":"Bissonnette","year":"2025","journal-title":"N Engl J Med"},{"issue":"10510","key":"10.1016\/j.jaad.2026.07.093_bib8","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(25)01576-4","article-title":"Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2)","volume":"406","author":"Gold","year":"2025","journal-title":"Lancet"},{"issue":"10284","key":"10.1016\/j.jaad.2026.07.093_bib9","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/S0140-6736(21)00440-2","article-title":"IL17A\/F nanobody sonelokimab in patients with plaque psoriasis: a multicentre, randomised, placebo-controlled, phase 2b study","volume":"397","author":"Papp","year":"2021","journal-title":"Lancet"},{"issue":"10284","key":"10.1016\/j.jaad.2026.07.093_bib10","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0140-6736(21)00873-4","article-title":"Nanobody cytokine blockers in psoriasis","volume":"397","author":"Rubel","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.jaad.2026.07.093_bib11","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1038\/s41591-025-03971-6","article-title":"Sonelokimab, an IL-17A\/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial","volume":"31","author":"McInnes","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jaad.2026.07.093_bib12","series-title":"International Nonproprietary Names (INN) for Biological and Biotechnological Substances (A Review). WHO\/MHP\/HPS\/INN\/2022.02","year":"2022"},{"issue":"2","key":"10.1016\/j.jaad.2026.07.093_bib13","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa2102383","article-title":"Bimekizumab versus secukinumab in plaque psoriasis","volume":"385","author":"Reich","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jaad.2026.07.093_bib14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4103\/0378-6323.181466","article-title":"Severe recalcitrant psoriasis treated with itolizumab, a novel anti-CD6 monoclonal antibody","volume":"82","author":"Gupta","year":"2016","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"1","key":"10.1016\/j.jaad.2026.07.093_bib15","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2026.07.093_bib16","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1056\/NEJMoa2408792","article-title":"Remibrutinib in chronic spontaneous urticaria","volume":"392","author":"Metz","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2026.07.093_bib17","series-title":"Nonproprietary Naming of Biological Products: Guidance for Industry","year":"2019"},{"issue":"3","key":"10.1016\/j.jaad.2026.07.093_bib18","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2337\/ds19-0065","article-title":"Naming convention, interchangeability, and patient interest in biosimilars","volume":"33","author":"Socal","year":"2020","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.jaad.2026.07.093_bib19","series-title":"Biosimilars in the EU: Information Guide for Healthcare Professionals. EMA\/837805\/2011, Rev. 5","year":"2019"},{"issue":"2","key":"10.1016\/j.jaad.2026.07.093_bib20","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4161\/mabs.3.2.14785","article-title":"Biosimilar, biobetter and next generation therapeutic antibodies","volume":"3","author":"Beck","year":"2011","journal-title":"MAbs"},{"issue":"5","key":"10.1016\/j.jaad.2026.07.093_bib21","doi-asserted-by":"crossref","first-page":"456","DOI":"10.4103\/ijmr.IJMR_43_18","article-title":"Similar biologics in India: a story of access or potential for compromise?","volume":"152","author":"Jois R","year":"2020","journal-title":"Indian J Med Res"},{"issue":"5","key":"10.1016\/j.jaad.2026.07.093_bib24","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s13555-025-01383-5","article-title":"CT-P17 adalimumab biosimilar in patients with moderate-to-severe chronic plaque psoriasis: an open-label extension of a phase 3 interchangeability study","volume":"15","author":"Pariser","year":"2025","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"8","key":"10.1016\/j.jaad.2026.07.093_bib25","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/1346-8138.17329","article-title":"Comparative study of efficacy and safety: biosimilar rituximab versus originator rituximab in the treatment of pemphigus","volume":"51","author":"Shin","year":"2024","journal-title":"J Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2026.07.093_bib26","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1080\/14712598.2019.1636963","article-title":"Biosimilars for the treatment of psoriasis","volume":"19","author":"Puig","year":"2019","journal-title":"Expert Opin Biol Ther"},{"issue":"14","key":"10.1016\/j.jaad.2026.07.093_bib27","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1056\/NEJMoa040528","article-title":"Pure red-cell aplasia and epoetin therapy","volume":"351","author":"Bennett","year":"2004","journal-title":"N Engl J Med"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226032044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962226032044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:26:48Z","timestamp":1793370408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962226032044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":23,"alternative-id":["S0190962226032044"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2026.07.093","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decoding biological drug names in dermatology: The post-2022 WHO nomenclature revision and its implications for clinical practice","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2026.07.093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}